Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma

摘要

Hepatocellular carcinoma (HCC) is one of the leading cause of cancer mortality worldwide. Patients diagnosed at early stage of HCC have good prognosis once receiving curative therapy including surgery or radiofrequency ablation. ' However, most patients are diagnosed in advanced stage making curative therapy not amenable. Sorafenib, a mul- tikinase inhibitor multikinase inhibitor for suppressing neoangiogenesis and cancer cell proliferation, showed survival benefit for patients with portal vein tumor throm- bosis or extra-hepatic metastases.* Chou et al. reported using ?-fetoprotein level to predict response to systemic therapy for advanced HCC.’ We presented a case of HCC with retroperitoneal lymph node metastasis with good tumor response to combination therapy with sorafenib and external radiotherapy but with severe complication afterward.